identified as target antibodies for many monoclonal antibodies raised against breast carcinoma cells (e.g., CA 15.3) or human milk fat globule membranes (Price et al., 1985) ; they also react with normal tissue, particularly luminal surfaces of glandular epithelia (Ellis et al., 1984) . Their relevance to clinical studies in breast cancer is that they are detectable in the serum of patients with metastatic disease. Early reports indicated that CA 15.3 levels were raised in patients with breast cancer compared to controls (Hayes et al., 1986; PonsAnicet et al., 1987) , that the percentage of breast cancer patients with elevated levels increases with stage of disease (Kerin et al., 1989) and that CA 15.3 might be useful for monitoring response to therapy (Sacks et al., 1987; Tondini et al., 1988) .
EMCA (epithelial membrane core antigen) monoclonal antibody, also known as C595 and NCRC-48, arose out of an investigation to produce a 'second generation' IgG monoclonal antibody against mucin antigens bearing the NCRC-11 defined epitope . The (British Breast Group, 1974 Biochemical assessment of response to therapy was assessed in the same manner as for all serum markers studied in patient received therapy was related to the pre-treatment baseline value of the marker and the inter-assay coefficient (CV) of the marker (<10% for each marker). A cut-off for each marker of the mean ± 2 s. (Table III) . In order to examine parallelism within the assay, three patient samples were assayed both undiluted and diluted with a zero calibrator; observed and expected values are presented (Table  IV) .
CA 15.3 assay precision Intra-assay variation was estimated with sera containing low (mean 7.8 U ml-'), medium (mean 30 U ml-') and high values (mean 723 U ml-') of CA 15.3; CVs were 6.9, 5.5 and 4% respectively. The inter-assay CV estimated using the quality control standard of 30 U ml-' supplied in the manufacturer's kit and a serum sample taken from the start of the study with a moderately high value (782 U ml-) were 9.2 and 7.4% respectively. Examination of the CA 15.3 standard curve suggested that the assay was not performing well from 150 U ml onwards; the curve was flattening off. A comparison was then undertaken of values from 25 patients with prediluted serum samples >140 U ml' and those obtained after performing a further dilution (x 10) step (Figure 1 ). Despite the commercial kit having an upper standard of 240 U ml-' the assay is not linear at concentrations >140 U ml -; correlation coefficient 0.7. For the purpose of this study subsequent samples were diluted where possible to ensure that there concentration at assay was within this range; linearity was observed at dilutions of 1, 0.8, 0.6, 0.4, 0.2 and 0 with concentrations >140 U ml-' (data not shown).
Markers in serum An excellent correlation was observed between changes in pre-treatment EMCA levels and serum measurements performed at 2, 4 and 6 months and the UICC assessment of response at 6 months; sensitivity 80%; specificity 91%; positive predictive value 84% and negative predictive value 89% at 2 months. The selectivity of the EMCA assay for this cohort of patients with systemic disease was acceptable at 70%. The corresponding values obtained at 4 month assessment were 91%, 92%, 91% and 92% respectively with a selectivity of 72%. The corresponding correlation of CA 15.3 against response for the same sub-set of patients is outlined in (Hayes et al., 1986; Kerin et al., 1989; Pons-Anicet et al., 1987; Tondini et al., 1988) confirming CA 15.3 to be a powerful marker of therapeutic response to endocrine (Robertson et al., 1990 (Robertson et al., , 1992 and cytotoxic chemotherapy (Dixon et al., 1993) . This assay utilises two monoclonal antibodies namely 11 5D8, produced by immunisation against milk fat globule membranes and DF3 prepared against breast carcinoma subcellular membranes. These two antibodies react with the same class of PEM antibody as the EMCA antibody. Comparative studies with 11 5D8 however, have shown that the epitopes defined by this antigen are separate and distinct from those defined by EMCA, the two assays measuring epithelial antigens by detection of different determinants . In summary, this preliminary study has shown that serum epithelial mucin core antigen (EMCA) appears to reflect tumour bulk and can be used to accurately monitor systemic therapy in patients with advanced breast cancer. Apart from a slight reduction in patient selectivity, EMCA produces comparable results to the more established CA 15.3. EMCA is potentially a very important marker in that the assay is much easier to perform than the CA 15.3 ELSA in only having two half hour incubations. The ELISA format also avoids the potential dangers associated with immunoradiometric assays. With the EMCA reagents having a long shelflife and a variably sized solid phase component, the assay is particularly suitable for rapid turnover of individual patient assays at no added cost. The assay also appears to be more robust than the CA 15.3 kit in that linearity is observed over the whole analyte range.
